Blood Reviews
Volume 23, Issue 2 , Pages 87-93 , March 2009

Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma

  • Antonio Palumbo

      Affiliations

    • Divisione di Ematologia dell’Università di Torino, Azienda Ospedaliera S. Giovanni Battista, Turin, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 0116336107; fax: +39 0116963737.
    • ,
  • Meletios Dimopoulos

      Affiliations

    • Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    • Tel.: +30 210 3381541; fax: +30 210 3381511.
    • ,
  • Jesus San Miguel

      Affiliations

    • Department of Hematology, University Hospital of Salamanca, Salamanca, Spain
    • Tel.: +34 923291384.
    • ,
  • Jean-Luc Harousseau

      Affiliations

    • Hôtel-Dieu Hospital, Nantes, France
    • Tel.: +33 2 40 08 32 71; fax: +33 2 40 08 32 50.
    • ,
  • Michel Attal

      Affiliations

    • Division of Hematology, Centre Hospitalier Université de Purpan, Toulouse, France
    • Tel.: +33 (05) 61777784; fax: +33 (05) 61777541.
    • ,
  • Mohamad Hussein

      Affiliations

    • H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA
    • Tel.: +1 813 745 8090; fax: +1 813 979 3071.
    • ,
  • Stefan Knop

      Affiliations

    • Department of Hematology and Oncology, University Hospital, Würzburg, Germany
    • Tel.: +49 931 201 0; fax: +49 931 201 70281.
    • ,
  • Heinz Ludwig

      Affiliations

    • Wilhelminenspital, Vienna, Austria
    • Tel.: +43 1491502101; fax: +43 1491501009.
    • ,
  • Marie von Lilienfeld-Toal

      Affiliations

    • BMTU, Gledhow Wing, St. James’s University Hospital, Leeds Teaching Hospitals, Leeds, UK
    • Tel.: +44 228 28715507; fax: +44 228 28714319.
    • ,
  • Pieter Sonneveld

      Affiliations

    • Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands
    • Tel.: +31 10 463 3123; fax: +31 10 463 5814.

References 

  1. Piazza FA, Gurrieri C, Trentin L, Semenzato G. Towards a new age in the treatment of multiple myeloma. Ann Hematol. 2007;86:159–172
  2. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21–33
  3. National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in OncologyTM. Multiple Myeloma. V.1.2008. <www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf> [accessed 4.10.2007].
  4. Smith A, Wisloff F, Samson D. UK Myeloma Forum; Nordic Myeloma Study Group; British Committee for Standards in Haematology. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol. 2006;132:410–451
  5. Kumar S, Rajkumar SV. Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur J Cancer. 2006;42:1612–1622
  6. Kastritis E, Dimopoulos MA. The evolving role of lenalidomide in the treatment of hematologic malignancies. Expert Opin Pharmacother. 2007;8:497–509
  7. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4:314–322
  8. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100:3063–3067
  9. Richardson P, Jagannath S, Hussein M, et al. A multicenter, single-arm, open-label study to evaluate the efficacy and safety of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma; preliminary results. Blood (ASH Annual Meeting Abstracts) 2005; 106: [Abstract 1565].
  10. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006;108:3458–3464
  11. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Lenalidomide in multiple myeloma. Expert Rev Anticancer Ther. 2006;6:1165–1173
  12. Weber DM, Chen C, Niesvizky R, et al. For the Multiple Myeloma-009 Study Investigators. Oral lenalidomide plus dexamethasone for relapsed/refractory multiple myeloma. N Eng J Med. 2007;357:2133–2142
  13. Dimopoulos M, Spencer A, Attal M, et al. For the Multiple Myeloma-010 Study Investigators. Lenalidomide plus dexamethasone versus dexamethasone alone for relapsed or refractory multiple myeloma. N Eng J Med. 2007;357:2123–2132
  14. Bartlett JB, Tozer A, Stirling D, Zeldis JB. Recent clinical studies of the immunomodulatory drug (IMiD®) lenalidomide. Br J Cancer. 2005;93:613–619
  15. Anagnostopoulos A, Dimopoulos MA, Spencer A, et al. A randomized phase 3 trial of oral lenalidomide and dexamethasone versus placebo and dexamethasone in patients with relapsed or refractory multiple myeloma. Final analysis of MM010 study. Haematologica. 2007;92(s2):[Abstract PO-661]
  16. Celgene Corporation, 2005. Revlimid® prescribing information. <www.revlimid.com/pdf/REVLIMID_PI.pdf> [accessed 4.10.2007].
  17. Chen C, Reece DE, Siegel D, et al. Expanded access program (EAP) for lenalidomide (Revlimid®) plus dexamethasone in over 1400 subjects with relapsed or refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2006; 108: [Abstract 3556].
  18. Lacy MQ, Gertz MA, Dispenzieri A, et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc. 2007;82:1179–1184
  19. Weber D, Wang M, Chen C, et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of 2 phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function. Blood (ASH Annual Meeting Abstracts) 2006; 108: [Abstract 3547].
  20. Bennett CL, Angelotta C, Yarnold PR, et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA. 2006;296:2558–2560
  21. Knight R, DeLap RJ, Zeldis JB. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med. 2006;354:2079–2080
  22. Rajkumar SV, Blood E. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med. 2006;354:2079–2080
  23. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005;106:4050–4053
  24. Rajkumar SV, Jacobus S, Callander N, et al. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol (ASCO Annual Meeting Abstracts) 2007; 25 (June 20 Suppl.): [Abstract LBA8025].
  25. Sviggum HP, Davis MD, Rajkumar SV, Dispenzieri A. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Arch Dermatol. 2006;142:1298–1302
  26. Stadtmauer E, Weber D, Dimopoulos M, et al. Lenalidomide in combination with dexamethasone is more effective than dexamethasone at first relapse in relapsed multiple myeloma. Blood (ASH Annual Meeting Abstracts). 2006;108:[Abstract 3552]
  27. Chanan-Khan AA, Yu Z, Weber D, et al. Lenalidomide (L) in combination with dexamethasone (D) significantly improves time to progression (TTP) in non-stem cell transplant patients (pts) with relapsed or refractory (rel/ref) multiple myeloma (MM): analysis from MM-009 and MM-010 randomized phase III clinical trials. Blood (ASH Annual Meeting Abstracts) 2006; 108: [Abstract 3554].
  28. Wang M, Knight R, Dimopoulos M, et al. Effect of Len/Dex in MM despite Thal resistance. Haematologica. 2007;92(s2):[Abstract PO-662]
  29. Bahlis NJ, Mansoor A, Lategan JC, et al. Lenalidomide overcomes poor prognosis conferred by deletion of chromosome 13 and t(4;14) in multiple myeloma: MM016 trial. Blood (ASH Annual Meeting Abstracts) 2006; 108: [Abstract 3557].
  30. Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Björkholm M. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol. 2007;25:1993–1999
  31. Chanan-Khan AA, Weber D, Dimopoulos M, et al. Lenalidomide (L) in combination with dexamethasone (D) improves survival and time to progression in elderly patients (pts) with relapsed or refractory (rel/ref) multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts) 2006; 108: [Abstract 3551].
  32. Lonial S, Knight R, Dimopoulos M, et al. Effect of Len/Dex in MM in different age groups. Haematologica. 2007;92(s2):[Abstract PO-663]
  33. Chen N, Lau H, Kong L, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol. 2007;47:1466–1475
  34. US Food and Drug Administration. Information on Erythropoiesis Stimulating Agents (ESA). <www.fda.gov/cder/drug/infopage/RHE/default.htm> [accessed 8.1.2008].
  35. Cunningham RS. Therapeutic options for the treatment of cancer-associated thrombosis. Semin Oncol Nurs. 2005;21(4 Suppl 1):21–40
  36. Zangari M, Barlogie B, Thertulien R, et al. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin Lymphoma. 2003;4:32–35
  37. Srkalovic G, Cameron MG, Rybicki L, Deitcher SR, Kattke-Marchant K, Hussein MA. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer. 2004;101:558–566
  38. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005;104:2822–2829
  39. Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol. 2006;24:484–490
  40. Niesvizky R, Spencer A, Wang M, et al. Increased risk of thrombosis with lenalidomide in combination with dexamethasone and erythropoietin. J Clin Oncol (ASCO Annual Meeting Abstracts). 2006;24:(June 20 Suppl.): [Abstract 7506]
  41. Baz R, Li L, Kottke-Marchant K, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc. 2005;80:1568–1574
  42. Baz R, Walker E, Karam MA, et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol. 2006;17:1766–1771
  43. Zonder JA, Durie BG, McCoy J, et al. High incidence of thrombotic events observed in patients receiving lenalidomide (L) + dexamethasone (D) (LD) as first-line therapy for multiple myeloma (MM) without aspirin (ASA) prophylaxis. Blood (ASH Annual Meeting Abstracts). 2005;106:[Abstract 3455]
  44. Hussein MA. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thromb Haemost. 2006;95:924–930
  45. Fitzmaurice DA, Blann AD, Lip GY. Bleeding risks of antithrombotic therapy. BMJ. 2002;325:828–831
  46. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002;162:1729–1735
  47. Lee AY, Levine MN, Baker RI, et al. Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146–153
  48. Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006;144:673–684
  49. Oken MM, Pomeroy C, Weisdorf D, Bennett JM. Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med. 1996;100(6):624–628
  50. Thornburg A, Abonour R, Smith P, Knox K, Twigg HL. Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide. Chest. 2007;131:1572–1574
  51. Boccadoro M, Palumbo A, Bringhen S, et al. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica. 2002;87:846–850
  52. Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia. 2007;21:2035–2042
  53. National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in OncologyTM. Cancer-Related Fatigue. V.4.2007. <www.nccn.org/professionals/physician_gls/PDF/fatigue.pdf> [accessed 4.10.2007].

PII: S0268-960X(08)00063-5

doi: 10.1016/j.blre.2008.07.003

Blood Reviews
Volume 23, Issue 2 , Pages 87-93 , March 2009

Article Tools